FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Antagonist topics
Antagonist
Recurrence
Proliferative Disorder
Proliferative
Antibodies
Progesterone
Dicyclomine
Scopolamine
Extracellular
Pharmaceutically Acceptable Salt
Metalloprotein
Nucleic Acids
Polynucleotide
Nucleic Acid
Monoclonal

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antagonist patents



      
           
This page is updated frequently with new Antagonist-related patent applications. Subscribe to the Antagonist RSS feed to automatically get the update: related Antagonist RSS feeds. RSS updates for this page: Antagonist RSS RSS


Date/App# patent app List of recent Antagonist-related patents
02/26/15
20150057437
 Anti-cd40 antibody mutants patent thumbnailAnti-cd40 antibody mutants
A mutant of a potentially therapeutic anti-cd40 antibody is provided which mutant has reduced adcc and cdc activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-cd40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the adcc and/or cdc activities therein, and a mutant of an antagonistic anti-cd40 antibody, comprising at least one mutation or substitution in the constant region to reduce the adcc and/or cdc activities therein, both mutants having at least a hinge region derived from a human igg2..
Kyowa Hakko Kirin Co., Ltd.
02/26/15
20150057430
 Compound, use and method patent thumbnailCompound, use and method
The present invention relates to the use of an antagonist of kisspeptin in the manufacture of a medicament for the treatment of a condition induced and/or worsened by kisspeptin activity in an individual. The invention also provides certain defined peptide molecules, which may act as an antagonist of kisspeptin, which are of use in treating a condition induced and/or worsened by kisspeptin activity in an individual.
Medical Research Council
02/26/15
20150057360
 Methods for the treatment of tinnitus induced by cochlear excitotoxicity patent thumbnailMethods for the treatment of tinnitus induced by cochlear excitotoxicity
The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an nmda receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear.
Auris Medical Ag
02/26/15
20150057331
 Novel cellular targets for hiv infection patent thumbnailNovel cellular targets for hiv infection
Methods and compositions are provided for treating hiv infection and for inhibiting hiv infection, and for identifying purinergic receptor antagonists or panx 1 hemi-channel blockers useful therefor. The invention provides a method of treating a mammalian subject having an hiv infection, or suspected of having been exposed to hiv, comprising administering to the mammalian subject an amount of (i) an antagonist of a panx 1 hemichannel, or (ii) of an inhibitor of a purinergic receptor, effective to inhibit (a) hiv fusion with a target cell, or (b) hiv replication, or (c) hiv entry into a target cell, or two or more of (a), (b) and (c)..
Albert Einstein College Of Medicine Of Yeshiva University
02/26/15
20150057328
 Proline sulfonamide derivatives as orexin receptor antagonists patent thumbnailProline sulfonamide derivatives as orexin receptor antagonists
Wherein r1 and r2 are as described in the description, or pharmaceutically acceptable salts thereof, for use in the prevention or treatment of diseases or disorders related to the orexin system. The present invention also relates to the use of (s)-proline sulfonamide compounds of formula (ii) as pharmaceuticals, to pharmaceutical compositions comprising compounds of formula (ii), and especially their use in the prevention or treatment of diseases or disorders related to the orexin system..
02/26/15
20150057322
 Compounds containing s-n-valeryl-n--valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations patent thumbnailCompounds containing s-n-valeryl-n--valine and (2r,4s)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
A method for treatment of a cardiovascular or renal condition or disease with a specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a nepi.. .
Novartis Pharmaceuticals Corporation
02/26/15
20150057317
 Gabr-a2 diagnostic patent thumbnailGabr-a2 diagnostic
The present invention provides a method of selection of a patient, who is a candidate for treatment with an nmda antagonist drug, such as (s)-1-phenyl-2-(pyridin-2-yl)ethanamine or ketamine, whereby to predict an increased or decreased likelihood of response to the nmda antagonist. The invention provides a method for determining the sequence of gabr-a2 at any of four single nucleotide polymorphism (snp) sites known as rs3756007, rs11503016, rs17537359 or rs1372472.
Astrazeneca Ab
02/26/15
20150057315
 Methods for treatment of 16p11.2 microdeletion syndrome patent thumbnailMethods for treatment of 16p11.2 microdeletion syndrome
Subjects that have a 16p11.2 microdeletion syndrome are treated by administering compositions that include mglur inhibitors, including mglur antagonists that include mglur negative allosteric modulators. Administration of compositions employed in the methods of the invention can treat psychiatric, including neuropsychiatric disorders, cognitive impairments, attention, obesity, intellectual disability and seizure disorders..
Massachusetts Institute Of Technology
02/26/15
20150057308
 Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives patent thumbnailFluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
The invention relates to fluorinated compounds and their use as integrin receptor antagonists. Novel fluorinated 3-(2-oxo-3-(3 -arylpropyl)imidazolidin-1-yl)-3 -arylpropanoic acid derivatives and pharmaceutically acceptable salts or solvates thereof and their use are described..
Scifluor Life Sciences, Llc
02/26/15
20150057268
 Composition and  neuropeptide s receptor (npsr) antagonists patent thumbnailComposition and neuropeptide s receptor (npsr) antagonists
Neuropeptide s receptor antagonists are provided that bind in functional assays to neuropeptide s receptors; methods are provided for use of these antagonists in treatment of conditions or disease states that are ameliorated by blocking of the neuropeptide s receptor, including substance abuse and substance abuse relapse; and for use of neuropeptide s receptor antagonists in the manufacture of therapeutics and pro-drugs for therapeutics useful in disease states and conditions sensitive to binding of the neuropeptide s receptor.. .
Research Triangle Institute
02/26/15
20150057255

Use of nk-1 receptor antagonists in pruritus


The invention relates to methods for treating pruritus with nk-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising nk-1 receptor antagonists such as serlopitant.
Tigercat Pharma, Inc.
02/26/15
20150056217

Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4 associated disorders


The present invention relates to the use of a tlr9 agonist and/or a tlr4 antagonist and/or a nod2 agonist for treatment or prevention of disorders involving tlr4 activation, such as systemic sepsis and necrotizing enterocolitis.. .
University Of Pittsburgh - Of The Commonwealth System Of Highter Education
02/26/15
20150056207

Combination therapy with c-met and egfr antagonists


The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to combination therapies for the treatment of pathological conditions, such as cancer..
Genentech, Inc.
02/26/15
20150056200

Methods for increasing adiponectin


In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an actriib signaling pathway. Examples of such antagonists include actriib polypeptides, anti-actriib antibodies, anti-activin a and/or b antibodies, anti-myostatin antibodies, anti-gdf3 antibodies, and anti-bmp7 antibodies.
Acceleron Pharma, Inc.
02/26/15
20150056190

Diagnostic methods and compositions for treatment of cancer


The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients who are likely to be responsive to vegf antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods..
Genentech, Inc.
02/26/15
20150056163

Leukotoxin e/d as a new anti-inflammatory agent and microbicide


The present invention relates to methods for preventing or treating human immunodeficiency virus (hiv) infection, inflammatory conditions, and graft-versus-host-disease (gvhd) in a subject. Therapeutic compositions of the present invention comprise leukocidin e (luke) and/or d proteins or polypeptides.
New York University
02/19/15
20150051259

Pro-inflammatory mediators in diagnosis and treatment of pulmonary disease


Treatment and diagnostic methods are provided for pulmonary disease, including chronic obstructive pulmonary disease. Various pro-inflammatory mediators are elevated in a model of copd that can be used predict the presence of copd and/or subtypes of copd in human patients.
National Jewish Health
02/19/15
20150051248

Imidazolyl methyl piperidine t-type calcium channel antagonists


The present invention is directed to imidazolyl methyl piperidine compounds which are antagonists of t-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which t-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which t-type calcium channels are involved..
Merck Sharp & Dohme Corp.
02/19/15
20150051243

8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists


Wherein r2, r7, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds..
02/19/15
20150051240

Compositions of buprenorphine and μ antagonists


.. .
02/19/15
20150051239

Arylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists


This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in parkinson's disease, huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, irritable bowel syndrome, obesity and type-2 diabetes.
Abbvie Bahamas Limited
02/19/15
20150051234

Therapy for complications of diabetes


A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelia a (eta) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective eta receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective eta receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension.
Abbvie Deutschland Gmbh & Co. Kg
02/19/15
20150051192

Blocking of cue-induced drug reinstatement


A method of preventing drug use relapse by administering an effective amount of an α3β4 nicotinic antagonist to a mammal after an initial period of drug use, and preventing a relapse of drug use. A method of preventing drug use relapse due to cue inducement by administering an effective amount of an α3β4 nicotinic antagonist to a mammal after an initial period of drug use, and preventing a relapse of drug use during cue inducement.
Albany Medical College
02/19/15
20150051183

Conformationally constrained, fully synthetic macrocyclic compounds


The conformationally restricted, spatially defined macrocyclic ring system of formula (i) is constituted by three distinct molecular parts: template a, conformation modulator b and bridge c. Macrocycles described by this ring system i are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase.
Polyphor Ag
02/19/15
20150050732

Selective differentiation, identification, and modulation of human th17 cells


The embodiments provide for the modulation of both the differentiation and activity of human th17 cells. More specifically, human th17 cell differentiation can modulated by tgf-β and il-21, and their agonists and antagonists.
The Brigham And Women's Hospital, Inc.
02/19/15
20150050290

Method and pharmaceutical composition for use in the treatment or the prevention of aneurysm


The present invention relates to a compound which is an antagonist of il-1 beta or an inhibitor of il-1 beta expression for use in the treatment or the prevention of aneurysm. In another embodiment, the invention relates to a pharmaceutical composition for use in the treatment or the prevention of aneurysm comprising an antagonist of il-1 beta or an inhibitor of il-1 beta expression..
Universite Paris Descartes
02/19/15
20150050286

Anti-ngf antibodies and methods using same


The invention concerns anti-ngf antibodies (such as anti-ngf antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain..
Rinat Neuroscience Corp.
02/19/15
20150050267

Antagonist antibodies directed against calcitonin gene-related peptide and methods using same


The invention features methods for preventing or treating cgrp associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-cgrp antagonist antibody. Antagonist antibody g1 and antibodies derived from g1 directed to cgrp are also described..
Labrys Biologics, Inc.
02/12/15
20150045556

Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto


Novel processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto. The compounds prepared by the present processes may be useful, for example, as antagonists to the mu, kappa and delta opioid receptors, and thereby may be useful in the treatment of gastrointestinal motility disorders, and in preventing peripheral opiate induced side effects.
02/12/15
20150045551

Fused azole derivative


The present invention provides agents for treating or preventing diseases such as mood disorder, anxiety disorder, schizophrenia, alzheimer's disease, parkinson's disease, huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, alopecia. Specifically, the invention provides fused azole derivatives represented by general formula (i) or pharmaceutically acceptable salts thereof that have an antagonistic action against the arginine-vasopressin 1b receptor:.
Taisho Pharmaceutical Co., Ltd
02/12/15
20150045358

Pharmaceutical composition for treating disorders associated with insulin resistance


A pharmaceutical composition for treating disorders associated with insulin resistance is disclosed, and the composition comprises at least one inhibitor which is an effective agent to suppress endothelin-1-stimulated resistin gene expression through decreasing the endothelin-1-stimulated phosphorylation of proteins downstream of endothelin type a receptor, wherein the downstream signaling molecules comprise erk1/2, jnks, akt, and stat3 proteins, and wherein the inhibitor is selected from at least one antagonist of the endothelin type a receptor or downstream signaling proteins.. .
National Central University
02/12/15
20150045332

Novel sphingosine 1-phosphate receptor antagonists


That are useful in the treatment and prevention of conditions associated with such receptors. More specifically, the present invention relates to the synthesis and use of sphingosine 1-phosphate receptor 2 (s1p2) antagonists that are useful in the treatment of cancer, atherosclerosis, diabetic retinopathy, and other inflammatory diseases.
02/12/15
20150045318

Component and treating viral disease


A method for treating viral infection includes administering to a subject in need thereof a composition containing p2x receptor antagonists. The methods may achieve preventive or therapeutic effect on hand foot and mouth disease by inhibiting viruses.
Institut Pasteur Of Shanghai, Chinese Academy Of Sciences
02/12/15
20150044201

Cyclon expression for the identification and control of cancer cells


The present disclosure concerns a method for the identification of the presence or absence of cancer cells in a biological sample, more particularly a method for the identification of the susceptibility or resistance to a treatment with cd20 agonists of cancer cells in a biological sample, the methods including determining the level of expression of the gene cyclon in the cells and comparing the level of expression to the level of expression in a non-cancer cell, wherein a level of expression higher than the level of expression in a non-cancer cell is an indication of the presence of a cancer cell, more particularly an indication of cancer cells with a resistance to treatment with antagonists. Kits for the determination of a level of expression of the cyclon gene in a biological sample, a method for the identification of cyclon expression antagonists, and methods for treating patients are provided..
Centre Hospitalier Universitaire Grenoble
02/05/15
20150038707

Process for making cgrp receptor antagonists


Methods for preventing pest infestations are disclosed. In some embodiments, the methods for preventing infestations involve use of pyrethroid insecticides or the stereoisomers or salts thereof..
Merck Sharp & Dohme Corp.
02/05/15
20150038523

Integrin antagonist conjugates for targeted delivery to cells expressing alpha-v-beta-3


The invention relates to compounds of formula (i): wherein r1, r2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula (i) for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to alpha-v-beta-integrin antagonists to target cells expressing alpha-v-beta-3..
Hoffmann-la Roche Inc.
02/05/15
20150038502

Isoxazolopyridine orexin receptor antagonists


The present invention is directed to isoxazolopyndine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the isoxazolopyndine compounds described herein in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
Merck Sharp & Dohme Corp.
02/05/15
20150038468

Estrogen antagonists as treatments for sclerosing disorders


The present invention relates to methods and compositions for treating a subject suffering from a sclerosing disorder, comprising administering, to the subject, an effective amount of an estrogen receptor antagonist (“erant”), wherein said erant has essentially no estrogen receptor agonist activity under physiologic conditions.. .
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
02/05/15
20150038464

Methods of increasing light responsiveness in a subject with retinal degeneration


Disclosed herein are methods of increasing retinal responsiveness to light in a subject, such as a subject with retinal degeneration. The disclosed methods include administering one or more compounds that decrease or inhibit γ-aminobutyric acid (gaba) signaling to a subject with retinal degeneration.
The United States Government As Represented By The Department Of Veterans Affairs
02/05/15
20150038450

Combination therapy for the treatment of cancer


Described are methods and compositions for treating cancer that include a dopamine receptor (dr) antagonist such as thioridazine and a chemotherapeutic agent. Optionally, the chemotherapeutic agent is a dna synthesis inhibitor such as cytarabine or a microtubule inhibitor such as paclitaxel or docetaxel.
Mcmaster University
02/05/15
20150038423

Delivery of therapeutic agents by a collagen binding protein


Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. Methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a pth/pthrp receptor agonist are provided.
Montefiore Medical Center
02/05/15
20150037821

Methods of identifying hit-antibodies and pf4 antagonists and cell lines for use therein


Methods and cells or cell lines for identifying antibodies or fragments thereof that activate heparin-induced thrombocytopenia (hit) are described. The methods comprise contacting a hematopoietic cell or cell line that comprises, in operative association, the platelet receptor fcyriia under the control of a suitable promoter, and a reporter construct comprising a reporter gene under the control of a promoter and transcription factor, which transcription factor is regulated downstream of the signaling cascade of activated fcyriia, with a test sample from a mammalian subject; a platelet factor 4 (pf4), a wild-type or variant of pf4 or a fragment thereof; and heparin; and detecting or measuring the level of reporter gene expression..
The University Of Birmingham
02/05/15
20150037820

Lung cancer markers and uses thereof


Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (lcm). Individual lcm and panels comprising multiple lcm are provided for these and other uses.
Celera Corporation
01/29/15
20150031897

Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases


A method administers quaternary ammonium anti-cholinergic muscarinic receptor antagonists in combination with acetyl-cholinesterase inhibitors to treat either cognitive impairment or acute delirium. This therapy results in a modification of a cognitive disorder or disease, namely a slow down in the disease progression.
01/29/15
20150031893

An h3 receptor antagonist for use in the treatment of alzheimer's disease


This disclosure relates to methods of using 2-(cyclohexylmethyl)-n-{2-[(2s)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide in a disease modifying therapy of alzheimer's disease, other tauopathies and related neurodegenerative diseases.. .
Sanofi
01/29/15
20150031728

Cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures


Compositions of a cyclooxygenase inhibitor and a calcium channel antagonist in a liquid carrier. The composition may be administered the urinary tract during urological diagnostic, interventional, surgical and other medical procedures.
Omeros Corporation
01/29/15
20150031718

Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent


Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid.. .
Purdue Pharmaceuticals L.p.
01/29/15
20150031716

Piperidinone carboxamide azaindane cgrp receptor antagonists


The present invention is directed to piperidinone carboxamide indane derivatives which are antagonists of cgrp receptors and useful in the treatment or prevention of diseases in which the cgrp is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which cgrp is involved..
Merck Sharp & Dohme Corp.
01/29/15
20150031715

Integrin antagonist conjugates for targeted delivery to cells expressing vla-4


The invention relates to compounds of formula i: wherein r1, r2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula i for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to vla-4 integrin antagonists to target cells expressing vla-4..
Hoffmann-la Roche Inc.
01/29/15
20150031705

Ophthalmic formulations including selective alpha 1 antagonists


Ophthalmic formulations are provided. The ophthalmic formulations include one or more active agents that act to optimize pupil light reflex while minimizing, or effectively eliminating, any undesired eye redness in response to application thereof.
Ocularis Pharma, Llc
01/29/15
20150031689

Peripherally restricted diphenyl purine derivatives


The invention provides compounds capable of acting as antagonists at cannabanoid receptors according to the following formula: such compounds may be used to treat conditions for which the cannabinoid receptor system has been implicated, such as obesity, liver disease, diabetes, pain, and inflammation.. .
Research Triangle Institute
01/29/15
20150031688

Compositions of dual thyrointegrin antagonists and use in vascular-associated disorders


A dual thyrointegrin antagonist and a method for treating an angiogenesis-mediated disorder and/or a hyperthyroidism disorders by introducing the dual thyrointegrin antagonist into animals (e.g., mammals, human beings). The dual thyrointegrin antagonist includes a chemical structure having a thyroid hormone antagonist and αvβ3 integrin antagonist in the same molecule..
Vascular Vision Pharmaceutical Company
01/29/15
20150031605

Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof


The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin o-acyltransferase (goat) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (vii): a11-a12-a13-gly-ser-a14-phe-leu-a15-a16-a17-a18, wherein each of a11, a12, and a13 is independently absent, an amino acid, or an amino protecting group; each of a15, a16, a17, and a18 is independently absent or an amino acid; and a14 is a serine conjugated with a —c(o)c1-c20alky or a diaminopropionic acid conjugated with a —c(o)c1-c20alkyl group, provided that at least one of a11, a12, or a13 is present..
The Administrators Of The Tulane Educational Fund
01/29/15
20150031083

Adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis


The invention relates to an adenoviral-based biological delivery and expression system for use in the treatment or prevention of osteoathritis in human or mammalian joints by long-term inducible gene expression of human or mammalian interleukin-1 receptor antagonist (il-1ra) in synovial cells, comprising a helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin-1 receptor antagonist (il-1ra), left and right inverted terminal repeats (l itr and r itr), the adenoviral packaging signal and non-viral, non-coding stuffer nucleic acid sequences, wherein the expression of the human or mammalian interleukin-1 receptor antagonist (il-1ra) gene within synovial cells is regulated by an inflammation-inducible promoter.. .
Baylor College Of Medicine
01/29/15
20150030561

Use of cxcr4 antagonists


Presently disclosed are methods and compositions for treating or preventing whim syndrome and certain other disorders or conditions with a certain cxcr4 antagonist.. .
University Of Washington Center For Commercialization
01/22/15
20150025237

Methods and compounds useful in the synthesis of orexin-2 receptor antagonists


The present disclosure provides compounds and methods that are useful for the preparation of compounds useful as orexin-2 receptor antagonists.. .
Eisai R&r Management Co. Ltd.
01/22/15
20150025224

Antagonists of neuropilin receptor function and use thereof


The present invention relates to antagonists of neuropilin receptor function and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases.. .
Children's Medical Center Corporation
01/22/15
20150025223

System and producing interleukin receptor antagonist (ira)


The present invention relates to a system and method for producing high levels of autologous il-1ra cytokine, comprising: a blood collection vessel (1), a cover (4), a portion of separation gel (2), an anticoagulant portion (3), a plasma collection syringe comprising a sharp needle (9), a buffy coat collection syringe (11) and an incubation tube with cover (15). The vessel is adapted such that, when containing the whole blood (5), and centrifuged after treatment, yields separation fractions comprising, a first fraction of rbcs sediment (6), a second fraction of said gel (2), a third fraction comprising wbcs, platelets and), and fourth fraction of plasma solution (8)..
Estar Technologies Ltd
01/22/15
20150025153

Small molecule cmklr1 antagonists in demyelinating disease


Compounds and methods are provided for decreasing demyelinating inflammatory disease in a subject by inhibiting the activity of chemokine-like receptor 1 (cmklr1). In some embodiments such methods include treating demyelinating inflammatory disease in a subject by administering an agent that antagonizes the activity of chemokine-like receptor 1 (cmklr1) and/or a cmklr1 ligand (e.g., chemerin or other endogenous cmklr1 ligands).
The Board Of Trustees Of The Leland Stanford Junior University
01/22/15
20150025101

Opioid agonist/antagonist combinations


The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome)..
Purdue Pharma L.p.
01/22/15
20150025075

Heterocyclic amide derivatives as p2x7 receptor antagonists


Wherein r1, r2, r3, x and n are as defined in the description, their preparation and their use as pharmaceutically active compounds.. .
01/22/15
20150025064

Novel benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof


Wherein r1, r2, r4, r6, r7, r8, r9, and r10 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, methods of use of such compounds and compositions, and methods for preparing the compounds and compositions.
01/22/15
20150025061

Gabaa receptor antagonists affecting ganglion cell function and visual acuity


The present invention is directed to a method of enhancing visual acuity in a subject, comprising intravitreally administering to the subject in need of such enhancement, a therapeutically effective amount of an extrasynaptic gabaa receptor antagonist. The present invention is also directed to an ocular implant comprising a therapeutically effective amount of the extrasynaptic gabaa receptor antagonist..
Allergan, Inc.
01/22/15
20150025046

Preparation and use of bicyclic himbacine derivatives as par-1 receptor antagonists


The present invention relates to bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt thereof, wherein: x is —o—, —n(r), —c(r8)(r9) or —c(o)—; and y is —o—, —n(r), —c(r8)(r9) or —c(o)— and the remaining variables are described herein. The compounds of the invention are effective inhibitors of the par-1 receptor.
Merck Sharp & Dohme Corp.
01/22/15
20150025017

Compositions and methods for treating cancer


The present disclosure provides compositions and methods for treating cellular hyperproliferative disorders with a phf5α inhibitor, such as sirna, shrna, antisense oligonucleotides, or pharmaceutical compounds. Exemplary cellular hyperproliferative disorders that can be treated with the phf5α antagonists of the present disclosure include cancers, such as gliomas, adenocarcinomas, cervical cancer or prostate cancer..
Fred Hutchinson Cancer Research Center
01/22/15
20150025013

Compositions and methods of use for (pro)renin receptor


Disclosed are methods of treating kidney disease, infectious or inflammatory diseases, acute kidney injury and hypertension by administering a (pro)renin receptor (prr) antagonist. In some instances the prr antagonist is a polypeptide.
University Of Utah
01/22/15
20150024058

Pharmaceutical compositions for the deterrence and/or prevention of abuse


Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided..
Alpharma Pharmaceuticals Llc


Popular terms: [SEARCH]

Antagonist topics: Antagonist, Recurrence, Proliferative Disorder, Proliferative, Antibodies, Progesterone, Dicyclomine, Scopolamine, Extracellular, Pharmaceutically Acceptable Salt, Metalloprotein, Nucleic Acids, Polynucleotide, Nucleic Acid, Monoclonal

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Antagonist for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antagonist with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         









0.4291

3328

2 - 1 - 71